EPISODE · Jun 4, 2026
ONDINE BIOMEDICAL INC. - Results for the year ended 31 December 2025
from Investor Meet Company - Audio Archive · host Investor Meet Company
Ondine Biomedical Inc. reported FY2025 results highlighting a year of focused investment in clinical evidence generation, operational readiness and targeted commercial progress, with revenue increasing 29% to $2.6 million. The webcast centred on Ondine’s pivotal LANTERN Phase 3 study, which enrolled nearly 5,200 patients across 18 hospitals and is designed to support the company’s U.S. regulatory pathway for nasal photodisinfection, with top-line results expected by the end of Spring 2026. Management also discussed the growing body of real-world clinical and health economic evidence supporting Steriwave®, international adoption, manufacturing readiness and preparations for potential U.S. market entry as the company moves toward what it expects to be a pivotal year ahead.
What this episode covers
Ondine Biomedical Inc. reported FY2025 results highlighting a year of focused investment in clinical evidence generation, operational readiness and targeted commercial progress, with revenue increasing 29% to $2.6 million. The webcast centred on Ondine’s pivotal LANTERN Phase 3 study, which enrolled nearly 5,200 patients across 18 hospitals and is designed to support the company’s U.S. regulatory pathway for nasal photodisinfection, with top-line results expected by the end of Spring 2026. Management also discussed the growing body of real-world clinical and health economic evidence supporting Steriwave®, international adoption, manufacturing readiness and preparations for potential U.S. market entry as the company moves toward what it expects to be a pivotal year ahead.
NOW PLAYING
ONDINE BIOMEDICAL INC. - Results for the year ended 31 December 2025
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Feb 8, 2026 ·4m
Feb 4, 2026 ·18m
Jan 30, 2026 ·6m
Jan 2, 2026 ·47m